Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 710-722

  Laufer, Stefan A ^a   Domeyer, David M ^a   Scior, Thomas R F ^b   Albrecht, Wolfgang ^c   Hauser, Dominik R J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TEVA PHARMACEUTICALS   (Israel)

^c BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

ARTICLE; CHEMICAL BOND; COMPETITIVE INHIBITION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; PROTEIN PROTEIN INTERACTION; PROTEINASE INHIBITION;

ADENOSINE TRIPHOSPHATE; BINDING SITES; BINDING, COMPETITIVE; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13444272999     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0408767     Document Type: Article

References (48)

1. Hopkins, A. L.; Groom, C. R. Opinion: The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727-730.
2. Mueller, G. Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today 2003, 8, 681-691.
3. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The Protein Kinase Complement of the Human Genome. Science 2002, 298, 1912-1916, 1933.
4. Xie, X.; Gu, Y.; Fox, T.; Coll, J. T.; Fleming, M. A.; Markland, W.; Caron, P. R.; Wilson, K. P.; Su, M. S. S. Crystal structure of JNK3: A kinase implicated in neuronal apoptosis. Structure 1998, 6, 983-991.
5. Bellon, S.; Fitzgibbon, M. J.; Fox, T.; Hsiao, H. M.; Wilson, K. P. The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure Fold. Des 1999, 7, 1057-1065.
6. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell (Cambridge, MA) 2002, 109, 275-282.
7. Traxler, P. Tyrosine kinase inhibitors in cancer treatment (part II). Exp. Opin. Ther. Patents 1998, 8, 1599-1625.
8. Traxler, P. M. Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Patents 1997, 7, 571-588.
9. Adams, J. A. Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 2001, 101, 2271-2290.
10. Boehm, J. C.; Adams, J. L. New inhibitors of p38 kinase. Exp. Opin. Ther. Patents 2000, 10, 25-37.
11. Meijer, L.; Raymond, E. Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials. Acc. Chem. Res. 2003, 36, 417-425.
12. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. y.; Detivaud, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
13. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
14. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins: Struct., Funct., Genet. 1995, 22, 378-391.
15. Haesslein, J. L.; Jullian, N. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. Curr. Top. Med. Chem. 2002, 2, 1037-1050.
16. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a Purine-Scaffold Novel Class of Hsp90 Binders that Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
17. Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
18. Groom, C. R.; Hopkins, A. L. Protein kinase drugs-optimism doesn't wait on facts. Drug. Discov. Today 2002, 7, 801-802.
19. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
20. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10, 764-769.
21. Scapin, G.; Patel, S. B.; Lisnock, J.; Becker, J. W.; LoGrasso, P. V. The Structure of JNK3 in Complex with Small Molecule Inhibitors: Structural Basis for Potency and Selectivity. Chem. Biol. 2003, 10, 705-712.
22. www.upstate.com/features/kinaseprofiler.
23. Bader, H.; Chiang, Y. H. (Polaroid Corp.) 6-Chloropurine salts. U.S. Patent 4,405,781, 1981.
24. Robins, R. K.; Lin, H. H. Potential purine antagonists. IV. Synthesis of some 9-methyl-6-substituted purines. J. Am. Chem. Soc. 1957, 79, 490-494.
25. Davoll, J. Pyrrolo[2,3-d]pyrimidines. J. Am. Chem. Soc., Abstr. 1960, 131-138.
26. Cignarella, G.; Villa, S.; Barlocco, D. Synthesis of a new series of N-substituted-3-[1-alkyl(aryl)-4-piperidyl]azetidin-2-ones as possible muscarinic agents. J. Heterocycl. Chem. 1993, 30, 1337-1340.
27. Bredereck, H.; Effenberger, F.; Rainer, G. Acid amide reactions. XXXIV. 7-Substituted purines and their cleavage into 4,5-diaminopyrimidines. Justus Liebigs Ann. Chem. 1964, 673, 82-87.
28. Gundersen, L. L.; Bakkestuen, A. K.; Aasen, J.; Overas, H.; Rise, F. 6-Halopurines in palladium-catalyzed coupling with organotin and organozinc reagents. Tetrahedron 1994, 50, 9743-9756.
29. Robins, R. K.; Godefroi, E. F.; Taylor, E. C.; Lewis, L. R.; Jackson, A. Purine nucleosides. I. The synthesis of certain 6-substituted-9-(tetrahydro-2- pyranyl)purines as models of purine deoxynucleosides. J. Am. Chem. Soc. 1961, 83, 2574-2579.
30. Taylor, E. C.; Martin, S. F. General method for alkylation and alkenylation of heterocycles. J. Am. Chem. Soc. 1974, 96, 8095-8101.
31. Havelkova, M.; Dvorak, D.; Hocek, M. The Suzuki-Miyaura cross-coupling reactions of 2-, 6- or 8-halopurines with boronic acids leading to 2-, 6- or 8-aryl- and -alkenylpurine derivatives. Synthesis 2001, 1704-1710.
32. Boon, W. R.; Jones, W. G. M.; Ramage, G. R. Pteridines. I. An unambiguous synthesis of 7,8-dihydro-6-hydroxypteridines. J. Chem. Soc. 1951, 96-102.
33. Nolsoe, J. M. J.; Gundersen, L. L.; Rise, F. Synthesis of 8-halopurines by reaction of lithiated purines with appropriate halogen donors. Synth. Commun. 1998, 28, 4303-4315.
34. Beers, S. A., Malloy, E.; Wachter, M. P.; Wu, W. (Ortho-McNeil Corporation, Inc.) Preparation of substituted imidazoles useful in the treatment of inflammatory diseases. Patent WO 9847892 A1, 1998.
35. Cohen, P. The development therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 1999, 3, 459-465.
36. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
37. Miller, D. S.; Horowitz, S. B. Intracellular compartmentalization of adenosine triphosphate. J. Biol. Chem. 1986, 261, 13911-13915.
38. Laufer, S. A.; Wagner, G. K. From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release. J. Med. Chem. 2002, 45, 2733-2740.
39. Nishikawa, S.; Kumazawa, Z.; Kashimura, N.; Nishikimi, Y.; Uemura, S. Alternating dependency of cytokinin activity in the number of methylene units in .omega.-phenylalkyl derivatives of some purine cytokinins and 4-substituted pyrido[3,4-d]pyrimidine. Agric. Biol. Chem. 1986, 50, 2243-2249.
40. Keck, J. H., Jr.; Simpson, R. A.; Wong, J. L. Reactivities and electronic aspects of nucleic acid heterocycles. 7. Regiospecific substituent effects in 6-substituted purines as measured by proton magnetic resonance. J. Org. Chem. 1978, 43, 2587-2590.
41. Thompson, R. D.; Secunda, S.; Daly, J. W.; Olsson, R. A. N6,9-Disubstituted adenines: Potent, selective antagonists at the A1 adenosine receptor. J. Med. Chem. 1991, 34, 2877-2882.
42. Johnston, T. P.; Holum, L. B.; Montgomery, J. A. Synthesis of potential anticancer agents. XVI. S-Substituted derivatives of 6-mercaptopurine. J. Am. Chem. Soc. 1958, 80, 6265-6271.
43. Elion, G. B.; Lange, W. H.; Hitchings, G. H. Condensed pyrimidine systems. XVI. Purines and thiazolo[5,4-d]pyrimidines from 4-amino-5-formamido-6- mercaptopyrimidines. J. Am. Chem. Soc. 1956, 78, 2858-2863.
44. Montgomery, J. A.; Temple, C., Jr. Synthesis of potential anticancer agents. XXVI. The alkylation of 6-chloropurine. J. Am. Chem. Soc. 1961, 83, 630-635.
45. Kelley, J. L.; Krochmal, M. P.; Linn, J. A.; McLean, E. W.; Soroko, F. E. 6-(Alkylamino)-9-benzyl-9H-purines. A new class of anticonvulsant agents. J. Med. Chem. 1988, 31, 606-612.
46. Wojnar, R. J., Brittain, R. J.; Bernstein, J.; Losee, K. A. (Squibb and Sons E. R.) 9-Benzyladenine antiinflammatory agents and their use. U.S. Patent 3,930,005, 1973.
47. Aitken, R. A.; Drysdale, M. J.; Hill, L.; Lumbard, K. W.; MacCallum, J. R.; Seth, S. Flash vacuum pyrolysis of stabilised phosphorus ylides. Part 16. Model studies for the construction of conjugated polymers. Tetrahedron 1999, 55, 11039-11050.
48. Fuerstner, A.; Leitner, A.; Mendez, M.; Krause, H. Iron-Catalyzed Cross-Coupling Reactions. J. Am. Chem. Soc. 2002, 124, 13856-13863.